Tools
Tools
Kaneko, Kan, Miyaji, Eliane N., Gonçalves, Viviane M., Ferreira, Daniela 
ORCID: https://orcid.org/0000-0002-0594-0902, SolorzanoGonzalez, Carla, MacLoughlin, Ronan and Saleem, Imran
(2021)
'Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro'. International Journal of Pharmaceutics, Vol 599, p. 120407.
|
Text
1-s2.0-S0378517321002118-main.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
Abstract
Polymeric nanoparticles (NPs) are recognized as potential delivery vehicles for vaccines. PLGA is a biocompatible polymer synonymous with polymeric NPs, which can be coated with other polymers such as chitosan that has intrinsic adjuvant properties as well as mucoadhesive properties. Numerous modifications and variations exist for PLGA and chitosan, which can influence the NP characteristics and the resulting immunogenicity. The current study investigated variations for making chitosan coated PLGA NPs incorporating recombinant pneumococcal surface protein A from family 2, clade 4 (PspA4Pro) antigen as a vaccine targeting the vast majority of pneumococcal strains and determine the effect of the polymers on particle size, surface charge, and surface marker upregulation on a dendritic cell (DC) line in vitro. PLGA variations tested with the ester-terminal group had the greatest detriment for prospective vaccine use, due to the lowest PspA4Pro adsorption and induction of CD40 and CD86 cell surface markers on DCs. The negatively charged chitosans exhibited the lowest surface marker expressions, similar to the uncoated NP, supporting the commonly accepted notion that positive surface charge augments immunogenic effects of the NPs. However, the study indicated that NPs made from PLGA with an acid terminated group, and chitosan HCl salt, exhibit particle characteristics, antigen adsorption efficiency and immunogenicity, which could be most suitable as a vaccine formulation.
| Item Type: | Article |
|---|---|
| Subjects: | QU Biochemistry > QU 4 General works QV Pharmacology > Pharmaceutical Processes. Packaging. Labeling > QV 785 Types of pharmaceutical preparations. Dosage forms QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 573 Antigens QW Microbiology and Immunology > Immunotherapy and Hypersensitivity > QW 805 Vaccines. Antitoxins. Toxoids WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 217 Pneumococcal infections |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.1016/j.ijpharm.2021.120407 |
| Depositing User: | Stacy Murtagh |
| Date Deposited: | 09 Mar 2021 16:31 |
| Last Modified: | 17 Mar 2021 12:52 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/17220 |
Statistics
Actions (login required)
 |
Edit Item |